Latest Ratios: P/E Ratio 12.7x · EV/EBITDA N/A · ROE 19.6%. (2012–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $78M | $132M | $129M | $179M | $605M | $764M | $2.0B | $195M | $184M | $410M | $394M |
| Enterprise Value | $116M | $169M | $190M | $250M | $605M | $633M | $1.9B | $175M | $106M | $383M | $351M |
| P/E Ratio → | 12.72 | 23.25 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 99.37 | 167.28 | — | — | — | 5.27 | 58.85 | 5.66 | 6.52 | 12.78 | 18.12 |
| P/B Ratio | 1.63 | 2.98 | 9.37 | — | 56.13 | 5.81 | 11.19 | — | — | 6.76 | 2.97 |
| P/FCF | 90.64 | 152.58 | — | — | — | — | — | — | — | — | 17.59 |
| P/OCF | 70.19 | 118.16 | — | — | — | 114.22 | — | — | — | — | 8.98 |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 214.43 | — | — | — | 4.37 | 56.59 | 5.07 | 3.74 | 11.93 | 16.11 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 195.59 | — | — | — | — | — | — | — | — | 15.63 |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | -423.8% | -423.8% | — | — | — | 100.0% | -172.7% | 100.0% | -239.5% | -178.7% | -276.7% |
| Operating Margin | -11910.1% | -11910.1% | — | — | — | -44.5% | -265.3% | -208.3% | -354.8% | -284.7% | -426.5% |
| Net Profit Margin | 721.9% | 721.9% | — | — | — | -45.2% | -268.3% | -203.7% | -350.0% | -278.4% | -420.7% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 19.6% | 19.6% | 1.0% | — | -351.6% | -42.8% | -141.0% | — | -1563.8% | -92.5% | -54.2% |
| ROA | 4.1% | 4.1% | 0.1% | -32.2% | -71.1% | -18.8% | -37.5% | -55.6% | -63.8% | -38.7% | -37.4% |
| ROIC | -90.3% | -90.3% | -180.9% | -806.1% | -2440.3% | -96.6% | -429.2% | — | — | -112.0% | -63.2% |
| ROCE | -86.4% | -86.4% | -67.7% | -74.6% | -67.2% | -22.7% | -46.0% | -87.2% | -84.9% | -45.7% | -41.4% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.88 | 1.88 | 6.65 | — | 15.08 | 0.37 | 0.23 | — | — | 0.15 | 0.08 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | 0.84 | 4.41 | — | -0.04 | -0.99 | -0.43 | — | — | -0.45 | -0.33 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | 43.01 | — | — | — | — | — | — | — | — | -1.95 |
| Interest Coverage | — | — | — | -14.24 | -29.50 | -21.54 | -29.48 | -139.00 | -84.42 | -56.21 | -95.81 |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.56 | 2.56 | 0.94 | 1.78 | 2.28 | 3.69 | 5.79 | 2.18 | 2.20 | 4.90 | 6.51 |
| Quick Ratio | 2.56 | 2.56 | 0.94 | 1.48 | 2.28 | 3.69 | 5.79 | 2.18 | 2.20 | 4.90 | 6.51 |
| Cash Ratio | 2.37 | 2.37 | 0.75 | 1.30 | 2.12 | 3.53 | 5.46 | 2.06 | 2.04 | 4.74 | 6.34 |
| Asset Turnover | — | 0.01 | — | — | — | 0.41 | 0.10 | 0.26 | 0.23 | 0.17 | 0.08 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 166.54 | — | — | — | — | 103.15 | 18.88 | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 7.9% | 4.3% | — | — | — | — | — | — | — | — | — |
| FCF Yield | 1.1% | 0.7% | — | — | — | — | — | — | — | — | 5.7% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.0% | 0.0% |
| Shares Outstanding | — | $9M | $8M | $6M | $5M | $5M | $4M | $3M | $2M | $2M | $2M |
Binary clinical trial failure
Based on reported figures, the P/S ratio of 86.43 appears highly inflated, reflecting the company's transition to a minimal revenue base following the VOWST divestiture rather than any underlying growth, which suggests that traditional valuation multiples are currently ineffective for assessing this clinical-stage biotechnology entity.
The current valuation appears to be driven by speculative interest in the SER-155 pipeline rather than fundamental financial performance. Investors should monitor the forward EV/EBITDA of 13.10 with caution, as it likely relies on optimistic assumptions regarding future milestone payments that remain highly uncertain.
As reported in financial statements, the ROIC has consistently remained in negative territory, reaching -19.8% in 2026Q1, which indicates that the company is currently destroying shareholder value as it attempts to fund its specialized microbiome research platform without a sustainable commercial revenue stream to offset costs.
The persistent negative ROIC trend suggests that the firm's invested capital is not generating adequate returns, a common characteristic of early-stage biotech firms. This trend warrants further investigation into whether the company can achieve a positive return profile before its current cash reserves are fully exhausted.
According to recent SEC filings, the current ratio has fluctuated significantly, settling at 1.65 in 2026Q1, which suggests that while the company maintains a basic level of short-term solvency, its liquidity position remains vulnerable to the high cash burn associated with ongoing clinical development activities.
The reliance on current assets to cover liabilities appears precarious given the lack of recurring cash inflows. Investors should monitor the quick ratio closely, as any further depletion of cash reserves could necessitate dilutive financing to maintain the company's operational continuity.
Based on reported figures, the debt-to-equity ratio of 3.04 in 2026Q1 indicates a high degree of financial leverage relative to the company's shrinking equity base, which may limit management's ability to secure additional non-dilutive financing in the current high-interest rate environment.
The elevated leverage appears to be a byproduct of the company's need to bridge its funding gap following the divestiture of its primary commercial asset. This capital structure suggests that the firm is increasingly sensitive to interest rate volatility and potential credit market tightening.
The P/E ratio of 11.06 is the most commonly misapplied metric for this business model, as it obscures the reality that the company is currently a clinical-stage R&D entity rather than a profitable commercial enterprise, rendering earnings-based valuation entirely inappropriate for assessing its long-term viability.
Investors should instead focus on cash runway and the probability-weighted net present value of the clinical pipeline. Using P/E ratios for a company with negative operating margins and one-time accounting gains from asset sales leads to a fundamental misunderstanding of the firm's actual financial health.
Includes 30+ ratios · 14 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying MCRB stock.
Seres Therapeutics, Inc.'s current P/E ratio is 12.7x. The historical average is 23.3x.
Seres Therapeutics, Inc.'s return on equity (ROE) is 19.6%. The historical average is -94.6%.
Based on historical data, Seres Therapeutics, Inc. is trading at a P/E of 12.7x. Compare with industry peers and growth rates for a complete picture.
Seres Therapeutics, Inc. has -423.8% gross margin and -11910.1% operating margin.